The clinical diagnosis of inherited renal tubulopathies can be challenging, as they are rare characterized by significant phenotypic variability. Advances in sequencing technologies facilitate the establishment of a molecular diagnosis. We aimed to investigate the diagnostic yield of a next generation sequencing panel assessing relevant disease genes in children with a clinical diagnosis of a renal tubulopathy followed through three national networks. DNA was amplified with a kit provided by the European Consortium for High-Throughput Research in Rare Kidney Diseases with 9 multiplex PCR reactions producing 571 amplicons to cover 37 genes associated with tubulopathies, followed by massively parallel sequencing and bioinformatic interpretation. Identified mutations were confirmed by Sanger sequencing. Overall, we assessed 384 index patients and 16 siblings. Most common clinical diagnoses were Bartter/Gitelman syndrome (N=174) and distal renal tubular acidosis (N=76). A total of 269 different variants were identified in 27 genes, of which 95 were considered likely and 136 definitely pathogenic and 100 had not been described at annotation. These mutations established a genetic diagnosis in 245 (64%) of the index patients. . Genetic testing changed the clinical diagnosis in 16 (4%) of cases and provided insights into the phenotypic spectrum of the respective disorders.
Introduction
The renal tubules reabsorb the vast majority of the glomerular filtrate and in this way preserve the "milieu interieur" and maintain homeostasis critical for normal physiology. 1 This task is performed by an array of specialised transporters and channels, the dysfunction of which can lead to number of specific disorders, collectively referred to as tubulopathies. While tubulopathies can be inherited or acquired, identification of a genetic basis in inherited forms is desirable as it establishes a clear diagnosis, enabling specific work-up, genetic counselling and cascade screening of at-risk relatives.
Moreover, clinical observations in genetically stratified cohorts of patients not only help understanding of the role of the causal gene, but also enable collection of long-term outcome data that inform prognosis and management of patients affected by the respective disorder. 2 Previously, individual candidate genes based on clinical suspicion were sequenced; a process suitable if the clinical diagnosis is convincing and only a single gene needs to be screened. However, several tubulopathies can be caused by multiple genes and/or have phenotypic overlap with other disorders, such as Bartter and Gitelman syndromes or distal renal tubular acidosis, making a single gene approach cumbersome and expensive. With the advent of next generation sequencing (NGS), simultaneous sequencing of multiple genes has become feasible and is increasingly performed. Driven by the rapidly decreasing costs of NGS, whole exome or even whole genome sequencing is increasingly utilized, but panel sequencing of selected genes provides the advantage of achieving high coverage of genes of interest at lower cost. 3 The working group for tubulopathies in the European Consortium for High-Throughput
Research in Rare Kidney Diseases (EURenOmics) 4 designed a kit for targeted amplification of 37 known tubulopathy disease genes. Here we describe our experience with this kit in a cohort of 410 patients from 384 families, recruited predominantly from dedicated networks for renal tubulopathies centralized in London, Paris and Brussels.
Results

Gene amplification and sequencing
The depth and horizontal coverage of the panel were assessed after the first run (23 samples). All of the targeted regions were covered at > 30X except for exon one of OCRL and WNK1, both of which have a high GC content. These exons were assessed by Sanger sequencing in those patients with a clinical diagnosis compatible with one of these genes and no other identified causative mutation.
Patients
A total of 384 index patients and 26 siblings were assessed. The most common clinical diagnosis was "Bartter/Gitelman syndrome" (N=174) and dRTA (N=76), followed by Pseudohypoaldosteronism type 1 (PHA1, N=31) and Nephrogenic Diabetes Insipidus (NDI, N=23) and a genetic diagnosis could be established in 74, 58, 42 and 83%, respectively. A list of the clinical diagnoses, the respective number of patients and the diagnostic yield is provided in table 1.
Genes
A total of 37 known tubulopathy disease genes were assessed. The genes that most commonly provided a genetic diagnosis were SLC12A3 (63 patients), CLCNKB (29 patients), SLC12A1 and ATP6V0A4 (22 patients each). A list of the 37 genes, the number of different mutations identified and the number of patients, in whom they provided a genetic diagnosis is provided in 
Genetic revision of the clinical diagnosis
Genetic results lead to revision of the clinical diagnosis in 22 (16 index) patients (see table 3 ). Ten (4 index) patients with a clinical diagnosis of idiopathic hypercalciuria/nephrocalcinosis were found to have either heterozygous (N=7) or bi-allelic mutations (N=3) in SLC34A3, establishing a diagnosis of hypophosphatemic rickets with hypercalciuria (HHRH) or its carrier status. In 9 patients, the revision was from Bartter to Gitelman syndrome (N=6) or vice versa (N=3, all with mutations in CLCNKB). One patient with a clinical diagnosis of "Dent disease/rickets" (P151) and one with "hypokalemia" (P103)
were found to have distal renal tubular acidosis (dRTA) by genetic testing. Patient L70 had a clinical diagnosis of Gitelman syndrome, yet was found to have autosomal dominant tubulointerstitial kidney disease (ADTKD), based on a heterozygous deletion of HNF1B. A renal ultrasound at the age of 14 years was initially reported as normal, but on review showed increased echogenicity with reduced corticomedullary differentiation.
Discussion
We report the use of targeted amplification and NGS of 37 "tubulopathy genes" in a large multinational cohort of patients with childhood-onset renal tubulopathies. Our most striking finding is the high diagnostic yield, which far surpasses the experience in other disease areas. In steroidresistant nephrotic syndrome, the reported diagnostic yield varies between 23-30%, although it is far lower for patients presenting after the first year of life. 5, 6 In nephronophthisis-related ciliopathies the reported yield is around 20-25%, 7, 8 while it is even lower, around 5-15%, in CAKUT. 9, 10 Our high diagnostic yield is comparable to previously reported cohorts of patients with autosomal recessive dRTA and Gitelman syndrome. 11, 12 This is consistent with the concept that the vast majority of Interestingly, we noted a high conformity of clinical and genetic diagnosis suggesting that an accurate clinical diagnosis can be established in most cases. Renal tubulopathies are characterized by typical constellations of clinical and biochemical findings, which can pinpoint a diagnosis. [13] [14] [15] Although there was discrepancy between the clinical and genetic diagnosis in 22 cases, the revision was rarely substantial. In most cases the diagnosis changed from Bartter to Gitelman or vice versa. Phenotypic overlap between Bartter type 3 and Gitelman syndromes is well recognized. 16, 17 Of interest is the change in diagnosis in patient L70 from Gitelman syndrome to ADTKD. While electrolyte abnormalities, especially hypomagnesemia, but also hypokalemia have been previously associated with HNF1B mutations, this has been in patients with concurrent renal malformations, such as cystic dysplasia, which was not reported as present in the ultrasound from this patient. 18, 19 In addition, genetic testing established a specific diagnosis in several patients with a clinical diagnosis of idiopathic hypercalciuria/nephrocalcinosis, mostly on the basis of mutations in SLC34A3. Recessive mutations in this gene cause HHRH and carriers have been described to have hypercalciuria. 20 The establishment of a diagnosis of dRTA in the 2 patients with a clinical diagnosis of "hypokalemia" and "Dent disease/rickets" likely reflects the occasional difficulties in establishing a diagnosis of dRTA early in life, as well as an associated proximal tubulopathy, which we reported in two-thirds of patients with dRTA at initial presentation and appears to be linked to the acidosis. 21 Indeed, the features of the proximal tubulopathy disappeared with correction of the acidosis also in this patient. Overall, the high diagnostic yield and the lack of substantial revision of the diagnosis in the vast majority of cases suggests a high level of clinical expertise present in the respective tubulopathy networks.
Yet, even in cases where the clinical diagnosis was confirmed, there was occasional diagnostic uncertainty, where genetic testing helped clarify the situation: for instance, there were 2 patients (patients L103 and L104), who initially presented to their local hospital in the first month of life with failure to thrive and were found to have hyponatremia, hyperkalemia and acidosis with elevated aldosterone levels, suggesting a clinical diagnosis of PHA1. However, when the children were assessed in the tubulopathy clinic at 3 and 5 months of life, respectively, no abnormalities were found: the children were thriving with no apparent electrolyte abnormalities, normal distal potassium secretion (transtubular potassium gradient, TTKG > 8) and remained well also after weaning off the salt supplementation. Consequently, there was uncertainty about the etiology of the initial presentation.
There was no family history of PHA1 and an acquired form of PHA1 was considered, for instance in the context of a urinary tract infection, that had been unrecognised at the time of presentation (both had initially received antibiotics due to their poor clinical state). 22 Yet, in both cases we identified heterozygous mutations in NR3C2, the gene encoding the mineralocorticoid receptor, establishing a diagnosis of autosomal dominant PHA1. Spontaneous resolution of symptoms during childhood has been reported in this disorder, as well a high proportion of asymptomatic adult NR3C2 mutation carriers. 23 , 24 Yet, our experience here suggests that symptoms can disappear even as early as during the first few months of life. Carriers of such mutations nevertheless are reported to have lifelong increased plasma renin and aldosterone levels. 25 Consistent with this observation, aldosterone levels in our patients subsequently returned elevated (L103: 5100, L104: 2200, normal <700 pmol/l). Apart from providing an explanation for the initial severe presentation, in one of these cases, the genetic diagnosis had further direct clinical implications, as it allowed early diagnosis in a subsequently born sibling.
Other cases of diagnostic uncertainty were those of patients with complex phenotypes, i.e. with symptoms beyond the tubulopathy. For instance, the pregnancy with patient L19 was complicated by antenatally noted cardiac calcifications, as well as polyhydramnios. Postnatally, an annular calcification at the root of the aorta was seen, as well as nephrocalcinosis and she was noted to have hyperkalemia and hyponatremia, which over the first two weeks of life changed to the typical electrolyte constellation of Bartter syndrome with hypokalemic alkalosis. This evolution of electrolyte abnormalities was consistent with a diagnosis of Bartter syndrome type 2, but it was unclear whether the patient suffered from an unknown complex syndrome that included a Bartter-like tubulopathy, or whether there were two separate diagnoses: Bartter syndrome plus aortic calcification. Genetic testing identified a homozygous mutation in KCNJ1, thus suggesting the co-existence of two separate diseases in this offspring of a consanguineous marriage. recessive ATP6V1B1 mutations. Given that ATP6V1B1 is a recessive disease gene, the dRTA in these 3 patients was defined as "genetically unsolved". Yet, interestingly, this mutation has been described previously in only heterozygous state in patients with dRTA with (mild) or without hearing loss. 12, 26 None of these patients have a recognized family history of dRTA, arguing against a dominant negative effect, unless the mutation occurred de novo in all. We were only able to test the parents of patient L80, and both did not carry this variant, arguing for a de novo mutation. The variants are not reported in the ExAC browser and thus likely rare and present in these patients not just by coincidence. Further studies are needed to better understand a potential causality of this variant.
It is important to note that in this study only variants classified as "probably" or "definitely" An interesting finding is the large number of patients with a genetic diagnosis of Gitelman syndrome (N=73), accounting for almost 20% of the entire patient cohort and similar in number to patients with Bartter syndrome (N=72, all 4 tested subtypes combined) and substantially more than patients with dRTA (N=50, all 3 tested subtypes combined). Gitelman syndrome is sometimes considered a disorder mostly presenting in adulthood, but our findings clearly argue for its relevance in children, as well. 16 Our findings are consistent with the notion of Gitelman syndrome being the most common tubulopathy, even in children. 29 In contrast, the almost complete absence of patients with a clinical or genetic diagnosis of ADTKD is surprising and may represent a bias in our cohort. Whilst mutations in MUC1 were not tested for, due to the technical difficulties of identifying the recognized pathogenic variant by NGS, this mutation is very rare. 30 Patients with mutations in UMOD may predominantly present in adulthood, but mutations in HNF1B have been recurrently reported in children with clinical signs of a tubulopathy. 18, 31 Presumably, the usually concurrent renal malformation combined with the relatively easy availability of genetic testing for HNF1B in the three involved countries has led to a lack of referring of such patients to the laboratories, as most already had a genetic diagnosis.
Summary
In conclusion, we find that comprehensive genetic testing of childhood-onset renal tubulopathies establishes a likely genetic diagnosis in the majority 32 leading to challenges in diagnosis and treatment. 4 Our study suggests that genetic testing is highly likely to help establish a specific diagnosis in children with symptoms suggestive of a tubulopathy, allowing targeted management.
Methods
A detailed description of the methods is provided in the supplemental appendix.
Gene selection
In 2012, the tubulopathy working group of the European Consortium for High-Throughput Research in Rare Kidney Diseases (EURenOmics) met to decide on gene inclusion for a comprehensive genetic testing panel. At the time, the group identified a total of 37 genes, mutations in which were recognized causes of tubulopathies. Only these and no candidate genes were included in the panel (table 2) .
Patients
DNA samples from a total of 410 patients from 384 families were assessed. Included were patients with a clinical diagnosis of a tubulopathy that was made before the age of 18 years and was consistent with the 37 genes tested. Of these, 139 samples were analysed in London, 195 in Paris and 76 in Brussels. Informed consent for genetic testing was obtained by the respective treating physician after approval by the respective institutional review boards, in accordance with the Declaration of Helsinki.
An overview of the clinical diagnoses is provided in 
Controls
Samples were tested from 22 patients with known mutations in 17 different genes in the panel to determine the sensitivity of the assay. These "positive control" mutations included a spectrum of different types including missense, nonsense, splice site and whole exon deletions present in either homozygous, heterozygous and hemizygous state and are listed in supplemental table 4.
Laboratory
Genetic testing was performed in three clinical genetic laboratories:
1) The North East Thames Regional Genetics Services, located at GOSH, which is accredited to ISO 15189 standard by the relevant UK authority (UKAS reference 7883), allowing us to perform genetic testing on a clinical basis with provision of formal reports.
2) The laboratory of molecular genetics of the HEGP is accredited to ISO 15189 standard by the relevant French authority (COFRAC reference N°8-3147).
3) The laboratory of molecular and cellular biology at the IPG institute, which is accredited to ISO 15189 standard by the relevant Belgian authority (BELAC reference 381-MED).
Gene amplification and next generation sequencing
The 37 target genes were amplified with a total of 9 multiplex PCR reactions generating 571
amplicons. MASTR kits for multiplex PCR were developed and provided by Multiplicom 
Bioinformatic analysis
Bioinformatic analysis was performed by various in house pipelines in the three laboratories involved, 
Variant annotation
Identified variants were annotated by the three involved clinical genetic laboratories according to published guidelines. 36 Variants were considered disease-causing, if they were consistent with the inheritance pattern, if the gene in which they were identified was compatible with the clinical findings and if there was evidence, based on previous reports or prediction algorithms (SIFT, Align GVD, mutation taster and Polyphen2 for pathogenicity, so that variants were either classified as "likely pathogenic"(class 4) or "definitely pathogenic" (class 5). If available, segregation was assessed within the family to confirm pathogenicity. "Variants of uncertain significance" (class 3) were recorded but were not considered disease-causing for the purpose of this study.
Each variant identified and annotated in one laboratory was independently annotated by at least one of the other laboratories. For those variants with discordant annotation, final classification was reached by consensus of the three laboratories using the relevant guidelines. 36 
Mutation confirmation
All identified mutations were confirmed by Sanger sequencing. Primers for mutation confirmation were designed using Primer 3 software (http://bioinfo.ut.ee/primer3). Sequencing was performed according to standard methods for point mutations. 
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